Most clinical data comes from type 2 diabetes and cardiovascular outcome trials rather than inflammation-specific studies
Single molecule activates GLP-1, GIP and glucagon receptors simultaneously Albumin-binding domain for extended pharmacokinetic half-life Covalent linkage resistant to retro-Michael addition (avoids decoupling) Follows clinical validation of dual and triple agonists in metabolic disease The inventors of this patent are Patrick Soon-Shiong , Martin Robitaille , Bing Song from Albunext LLC
Retatrutide has produced an average weight loss of 28.7%, compared to 20.7% with Wegovys newer 7.2 mg dose and 14.9% with the 2.4 mg dose
Mounjaro offers several key benefits tailored to the needs of patients: 1
Plans L, Barrot C, Nieto E, Rios J, Schulze TG, Papiol S, et al
Selenoproteins and their impact on human health through diverse physiological pathways